Innovative Immunotherapy Abalos Therapeutics specializes in harnessing arenaviruses to develop advanced immuno-oncology treatments, presenting opportunities to collaborate on innovative viral-based cancer therapies that target primary tumors and metastases.

Funding & Growth With over 36 million dollars in funding and a revenue range of up to 10 million dollars, Abalos is in a growth phase, offering potential for partnerships in clinical development, licensing, or technology licensing to accelerate their pipeline.

Leadership & Expertise Led by experienced biotech executives and immunology pioneers, including recent C-level appointments, the company demonstrates a strong strategic direction, making them a promising partner for joint ventures, research collaborations, or strategic investments.

Recent Expansion Recent key hires and executive appointments indicate active expansion and focus on advancing drug discovery and manufacturing capabilities, creating opportunities to supply research tools, manufacturing services, or collaborate on clinical trials.

Technological Ecosystem Utilizing a robust tech stack, Abalos is well-equipped for digital engagement and data-driven research collaborations, offering avenues for integrated technology partnerships, research data sharing, or digital health solutions in cancer immunotherapy.